Sucampo Pharmaceuticals Company Profile (NASDAQ:SCMP)

About Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SCMP
  • CUSIP: 86490910
  • Web: www.sucampo.com
Capitalization:
  • Market Cap: $565.61 million
  • Outstanding Shares: 46,325,000
Average Prices:
  • 50 Day Moving Avg: $11.27
  • 200 Day Moving Avg: $10.67
  • 52 Week Range: $9.30 - $17.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 11.42
  • P/E Growth: 0.85
Sales & Book Value:
  • Annual Revenue: $247.08 million
  • Price / Sales: 2.27
  • Book Value: $0.57 per share
  • Price / Book: 21.23
Profitability:
  • EBIDTA: $107.68 million
  • Net Margins: -61.99%
  • Return on Equity: 56.58%
  • Return on Assets: 15.47%
Debt:
  • Debt-to-Equity Ratio: 11.06%
  • Current Ratio: 5.14%
  • Quick Ratio: 4.42%
Misc:
  • Average Volume: 491,462 shs.
  • Beta: 1.43
  • Short Ratio: 11.13
 

Frequently Asked Questions for Sucampo Pharmaceuticals (NASDAQ:SCMP)

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) announced its earnings results on Wednesday, August, 2nd. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $0.06. The business had revenue of $59.90 million for the quarter, compared to analysts' expectations of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The company's quarterly revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.24 EPS. View Sucampo Pharmaceuticals' Earnings History.

When will Sucampo Pharmaceuticals make its next earnings announcement?

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Sucampo Pharmaceuticals.

What guidance has Sucampo Pharmaceuticals issued on next quarter's earnings?

Sucampo Pharmaceuticals issued an update on its FY17 earnings guidance on Wednesday, August, 2nd. The company provided EPS guidance of $1.00-1.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.05. The company issued revenue guidance of $220-230 million, compared to the consensus revenue estimate of $233.60 million.

Where is Sucampo Pharmaceuticals' stock going? Where will Sucampo Pharmaceuticals' stock price be in 2017?

6 brokers have issued 1 year target prices for Sucampo Pharmaceuticals' shares. Their predictions range from $11.00 to $30.00. On average, they expect Sucampo Pharmaceuticals' stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Sucampo Pharmaceuticals.

What are analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, with acquisition of Vtesse, Sucampo added a late stage program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. The company has lowered its earnings guidance to incorporate the Vtesee acquisition." (7/4/2017)
  • 2. Maxim Group analysts commented, "Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $170M in cash & the rest in stock: total of $200M. There is also a contingent earn-out (payments in the mid-single digit to double-digit royalties on global net sales) of the product at increasing net sales levels." (4/3/2017)
  • 3. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
  • 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Who are some of Sucampo Pharmaceuticals' key competitors?

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:

  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer
  • Peter P. Pfreundschuh CPA, Chief Financial Officer, Principal Financial Officer
  • Max Donley, Executive Vice President of Human Resources
  • Thomas J. Knapp, Executive Vice President, Chief Legal Officer and Corporate Secretary
  • Matthias Alder, Executive Vice President
  • Stanley G. Miele, Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
  • Peter A. Kiener Ph.D., Chief Scientific Officer
  • Alex Driggs, Acting General Counsel, Corporate Secretary
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer
  • John H. Johnson, Lead Independent Director

Who owns Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Krensavage Asset Management LLC (6.09%), LSV Asset Management (5.17%), Vanguard Group Inc. (3.56%), Dimensional Fund Advisors LP (3.40%), NEA Management Company LLC (2.71%) and Royce & Associates LP (2.31%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Jason Patrick Meyenburg, Jones W Bryan, Matthias Alder, Peter Greenleaf and Sachiko Kuno. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Who sold Sucampo Pharmaceuticals stock? Who is selling Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Cornerstone Capital Management Holdings LLC., GSA Capital Partners LLP, Gotham Asset Management LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, Tudor Investment Corp ET AL and Nationwide Fund Advisors. Company insiders that have sold Sucampo Pharmaceuticals stock in the last year include Andrew P Smith, Daniel P Getman, Matthias Alder, Peter Greenleaf and Sachiko Kuno. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Who bought Sucampo Pharmaceuticals stock? Who is buying Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Rubric Capital Management LP, Vanguard Group Inc., Systematic Financial Management LP, Municipal Employees Retirement System of Michigan, Marshall Wace North America L.P., Royce & Associates LP and Bowling Portfolio Management LLC. Company insiders that have bought Sucampo Pharmaceuticals stock in the last two years include Jason Patrick Meyenburg and Jones W Bryan. View Insider Buying and Selling for Sucampo Pharmaceuticals.

How do I buy Sucampo Pharmaceuticals stock?

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $12.10.


MarketBeat Community Rating for Sucampo Pharmaceuticals (NASDAQ SCMP)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sucampo Pharmaceuticals (NASDAQ:SCMP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $18.00 (48.76% upside)

Analysts' Ratings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/21/2017Leerink SwannInitiated CoverageMarket Perform -> Outperform$14.00 -> $15.00HighView Rating Details
8/8/2017Maxim GroupReiterated RatingBuy$21.00 -> $23.00MediumView Rating Details
8/3/2017Roth CapitalSet Price TargetBuy$30.00MediumView Rating Details
5/4/2017Jefferies Group LLCLower Price TargetHold$13.00 -> $11.00MediumView Rating Details
4/4/2017MizuhoReiterated RatingBuy$14.00HighView Rating Details
3/10/2017WallachBeth CapitalLower Price TargetBuy$20.00 -> $15.00LowView Rating Details
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00N/AView Rating Details
5/4/2016GuggenheimReiterated RatingBuy$29.00N/AView Rating Details
11/6/2015HC WainwrightLower Price Target$36.00 -> $28.00N/AView Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Earnings by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Earnings History by Quarter for Sucampo Pharmaceuticals (NASDAQ SCMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017$0.26N/AView Earnings Details
8/2/2017Q2 2017$0.22$0.28$56.44 million$59.90 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.28$0.23$54.15 million$56.30 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.48$0.68$66.00 million$73.00 millionViewListenView Earnings Details
11/9/2016Q316$0.26$0.28$51.30 million$57.90 millionViewListenView Earnings Details
8/3/2016Q216$0.22$0.23$48.33 million$52.00 millionViewListenView Earnings Details
5/4/2016Q116$0.19$0.21$44.11 million$47.20 millionViewListenView Earnings Details
3/8/2016Q415$0.19$0.43$42.72 million$55.40 millionViewListenView Earnings Details
11/4/2015Q315$0.18$0.16$36.18 million$33.50 millionViewListenView Earnings Details
8/5/2015Q215$0.15$0.21$31.90 million$34.90 millionViewListenView Earnings Details
5/6/2015Q114$0.14$0.14$30.19 million$29.50 millionViewListenView Earnings Details
3/4/2015Q413$0.17$0.21$37.23 million$37.80 millionViewListenView Earnings Details
11/6/2014Q313$0.04$0.03$26.11 million$31.50 millionViewListenView Earnings Details
8/5/2014Q213$0.03$0.04$24.06 million$24.10 millionViewListenView Earnings Details
5/7/2014Q113$0.04$0.02$24.19 million$22.20 millionViewListenView Earnings Details
2/26/2014Q4($0.04)$0.06$22.75 million$24.50 millionViewListenView Earnings Details
3/13/2013Q4 2012$0.12$0.32$32.21 million$34.90 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)
2017 EPS Consensus Estimate: $0.97
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.23$0.29$0.25
Q2 20172$0.22$0.26$0.24
Q3 20172$0.23$0.27$0.25
Q4 20172$0.21$0.24$0.23
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Insider Ownership Percentage: 4.13%
Institutional Ownership Percentage: 55.44%
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/11/2017Sachiko KunoMajor ShareholderSell1,000,000$12.00$12,000,000.00View SEC Filing  
9/6/2017Jason Patrick MeyenburgInsiderBuy4,000$12.13$48,520.00View SEC Filing  
8/4/2017Jones W BryanInsiderBuy4,700$10.60$49,820.00View SEC Filing  
11/29/2016Daniel P GetmanDirectorSell20,000$16.86$337,200.00View SEC Filing  
11/29/2016Peter GreenleafCEOSell200,000$16.84$3,368,000.00View SEC Filing  
11/28/2016Matthias AlderEVPSell150,000$16.00$2,400,000.00View SEC Filing  
11/15/2016Andrew P SmithCFOSell1,766$15.58$27,514.28View SEC Filing  
8/28/2015Daniel P. GetmanDirectorSell30,000$28.14$844,200.00View SEC Filing  
7/20/2015Thomas J KnappInsiderSell64,528$23.43$1,511,891.04View SEC Filing  
3/12/2015William AshtonDirectorSell55,762$17.55$978,623.10View SEC Filing  
3/11/2015Anthony C CelesteDirectorSell65,966$17.34$1,143,850.44View SEC Filing  
12/16/2014Cary J ClaiborneCFOSell50,000$12.91$645,500.00View SEC Filing  
12/15/2014Cary J ClaiborneCFOSell7,100$12.89$91,519.00View SEC Filing  
8/7/2014Sachiko KunoMajor ShareholderSell181,727$6.28$1,141,245.56View SEC Filing  
8/4/2014Ryuji UenoMajor ShareholderSell140,873$6.02$848,055.46View SEC Filing  
7/31/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/30/2014S&R Technology Holdings, LlcMajor ShareholderSell300$6.25$1,875.00View SEC Filing  
7/25/2014Ryuji UenoMajor ShareholderSell16,155$6.26$101,130.30View SEC Filing  
7/23/2014Ryuji UenoMajor ShareholderSell5,845$6.29$36,765.05View SEC Filing  
7/22/2014S&R Technology Holdings, LlcMajor ShareholderSell2,500$6.25$15,625.00View SEC Filing  
7/21/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/18/2014S&R Technology Holdings, LlcMajor ShareholderSell15,000$6.27$94,050.00View SEC Filing  
4/29/2014S&R Technology Holdings, Llcmajor shareholderSell113,600$6.65$755,440.00View SEC Filing  
4/25/2014Sachiko Kunomajor shareholderSell118,700$6.69$794,103.00View SEC Filing  
3/18/2014Gayle DolecekDirectorSell1,200$8.03$9,636.00View SEC Filing  
2/27/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
1/17/2014Ryuji UenoCEOSell360,000$10.36$3,729,600.00View SEC Filing  
1/7/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
10/16/2013Sachiko KunoMajor ShareholderSell360,000$6.35$2,286,000.00View SEC Filing  
9/18/2013Ryuji UenoCEOSell38,462$5.69$218,848.78View SEC Filing  
9/3/2013Ryuji UenoCEOSell38,462$5.59$215,002.58View SEC Filing  
8/19/2013Ryuji UenoCEOSell38,462$6.04$232,310.48View SEC Filing  
8/6/2013Sachiko Kunomajor shareholderSell38,462$6.21$238,849.02View SEC Filing  
7/24/2013Ryuji UenoCEOSell38,462$6.52$250,772.24View SEC Filing  
7/9/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.48$249,233.76View SEC Filing  
6/24/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.61$254,233.82View SEC Filing  
6/10/2013Sachiko KunoMajor ShareholderSell38,462$7.29$280,387.98View SEC Filing  
5/28/2013Ryuji UenoCEOSell38,462$8.79$338,080.98View SEC Filing  
5/21/2013Cary J ClaiborneCFOSell4,640$9.52$44,172.80View SEC Filing  
5/20/2013Stanley G MieleSVPSell6,400$9.60$61,440.00View SEC Filing  
5/16/2013Stanley G MieleSVPSell48,600$9.67$469,962.00View SEC Filing  
5/15/2013Timothy I MaudlinDirectorBuy32,870$9.82$322,783.40View SEC Filing  
5/13/2013Sachiko KunoMajor ShareholderSell38,462$9.27$356,542.74View SEC Filing  
2/4/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$5.22$200,771.64View SEC Filing  
12/26/2012S&R Technology Holdings, LlcMajor ShareholderSell20,262$5.01$101,512.62View SEC Filing  
11/27/2012Sachiko KunoMajor ShareholderSell12,205$5.00$61,025.00View SEC Filing  
11/13/2012Sachiko KunoMajor ShareholderSell11,962$5.00$59,810.00View SEC Filing  
11/1/2012Sachiko KunoMajor ShareholderSell37,595$5.06$190,230.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Latest Headlines for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Source:
DateHeadline
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 17 at 4:40 AM
americanbankingnews.com logoSucampo Pharmaceuticals (SCMP) & Its Peers Head-To-Head Survey
www.americanbankingnews.com - September 16 at 4:24 AM
finance.yahoo.com logoETFs with exposure to Sucampo Pharmaceuticals, Inc. : September 14, 2017
finance.yahoo.com - September 14 at 9:46 AM
americanbankingnews.com logoInsider Selling: Sucampo Pharmaceuticals, Inc. (SCMP) Major Shareholder Sells 1,000,000 Shares of Stock
www.americanbankingnews.com - September 13 at 7:38 PM
streetinsider.com logoUPDATE: Cancer Prevention Pharmaceuticals Secures $9.5M in Additional Funding from Sucampo (SCMP) Following Phase 3 Trial Progress
www.streetinsider.com - September 12 at 9:31 AM
finance.yahoo.com logoCancer Prevention Pharmaceuticals Receives $9.5 Million in Additional Funding from Sucampo Following Phase 3 Trial Progress
finance.yahoo.com - September 12 at 9:31 AM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 12 at 9:31 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Quarterly Sales of $57.44 Million
www.americanbankingnews.com - September 11 at 3:50 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.25 EPS
www.americanbankingnews.com - September 9 at 10:30 PM
seekingalpha.com logoSucampo Firing Sales Torpedos - Seeking Alpha
seekingalpha.com - September 9 at 8:16 AM
nasdaq.com logoSucampo (SCMP) Up 17.1% Since Earnings Report: Can It ... - Nasdaq
www.nasdaq.com - September 9 at 8:16 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Insider Jason Patrick Meyenburg Buys 4,000 Shares
www.americanbankingnews.com - September 8 at 8:40 PM
finance.yahoo.com logoSucampo (SCMP) Up 17.1% Since Earnings Report: Can It Continue?
finance.yahoo.com - September 8 at 8:03 AM
globenewswire.com logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wells Fargo Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 31 at 9:51 AM
finance.yahoo.com logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Wells Fargo Healthcare Conference
finance.yahoo.com - August 31 at 9:51 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Quarterly Sales of $56.86 Million
www.americanbankingnews.com - August 24 at 8:06 AM
nasdaq.com logoHealth Care Sector Update for 08/21/2017: SCMP,CHRS,CRME - Nasdaq
www.nasdaq.com - August 23 at 11:19 AM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : August 22, 2017
finance.yahoo.com - August 23 at 11:19 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) to Post Q3 2017 Earnings of $0.27 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - August 23 at 8:10 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 23 at 4:44 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Now Covered by Analysts at Leerink Swann
www.americanbankingnews.com - August 21 at 8:08 AM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : August 17, 2017
finance.yahoo.com - August 17 at 2:28 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Earns "Buy" Rating from Maxim Group
www.americanbankingnews.com - August 8 at 8:56 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Insider Buys $49,820.00 in Stock
www.americanbankingnews.com - August 7 at 7:20 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. to Post FY2021 Earnings of $1.78 Per Share, Jefferies Group Forecasts (NASDAQ:SCMP)
www.americanbankingnews.com - August 7 at 10:22 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Given a $30.00 Price Target at Roth Capital
www.americanbankingnews.com - August 6 at 6:28 PM
americanbankingnews.com logoZacks: Analysts Anticipate Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Will Announce Quarterly Sales of $58.95 Million
www.americanbankingnews.com - August 6 at 7:34 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - August 5 at 10:58 AM
finance.yahoo.com logoSucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCMP-US : August 4, 2017
finance.yahoo.com - August 5 at 6:54 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Expected to Announce Earnings of $0.26 Per Share
www.americanbankingnews.com - August 4 at 8:03 AM
streetinsider.com logoSucampo Pharmaceuticals (SCMP) PT Raised to $23 at Maxim Group on 2Q Report; 'Solid Revenues... Transformation ... - StreetInsider.com
www.streetinsider.com - August 4 at 7:58 AM
nasdaq.com logoSucampo (SCMP) Q2 Earnings & Revenues Beat Estimates, Up Y/Y - Nasdaq
www.nasdaq.com - August 4 at 7:58 AM
americanbankingnews.com logoJefferies Group Brokers Lower Earnings Estimates for Sucampo Pharmaceuticals, Inc. (SCMP)
www.americanbankingnews.com - August 4 at 7:02 AM
finance.yahoo.com logoEdited Transcript of SCMP earnings conference call or presentation 2-Aug-17 12:30pm GMT
finance.yahoo.com - August 2 at 9:17 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Given a $23.00 Price Target at Maxim Group
www.americanbankingnews.com - August 2 at 6:28 PM
finance.yahoo.com logoSucampo Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 4:16 PM
finance.yahoo.com logoSucampo reports 2Q loss
finance.yahoo.com - August 2 at 4:16 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - August 2 at 12:40 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Updates FY17 Earnings Guidance
www.americanbankingnews.com - August 2 at 10:18 AM
americanbankingnews.com logoFinancial Analysis: Sucampo Pharmaceuticals (NASDAQ:SCMP) vs. Cerulean Pharma (DARE)
www.americanbankingnews.com - July 31 at 10:24 PM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 29 at 7:45 AM
seekingalpha.com logoSucampo: A Shift Toward Rare Diseases - Seeking Alpha
seekingalpha.com - July 29 at 7:06 AM
americanbankingnews.com logoSucampo Pharmaceuticals, Inc. (SCMP) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:41 AM
globenewswire.com logoSucampo Announces Second Quarter 2017 Earnings Call - GlobeNewswire (press release)
globenewswire.com - July 20 at 7:33 AM
finance.yahoo.com logoSucampo Announces Second Quarter 2017 Earnings Call
finance.yahoo.com - July 20 at 7:33 AM
streetinsider.com logoSucampo Pharma (SCMP) Names Karen Smith to Board of Directors - StreetInsider.com
www.streetinsider.com - July 19 at 7:38 AM
streetinsider.com logoSucampo Pharma (SCMP) Names Karen Smith to Board of Directors
www.streetinsider.com - July 19 at 7:38 AM
finance.yahoo.com logoDr. Karen Smith Joins Sucampo’s Board of Directors
finance.yahoo.com - July 19 at 7:38 AM
americanbankingnews.com logo$0.22 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - July 12 at 10:38 PM
finance.yahoo.com logoETFs with exposure to Sucampo Pharmaceuticals, Inc. : July 11, 2017
finance.yahoo.com - July 12 at 7:44 AM

Social

Chart

Sucampo Pharmaceuticals (SCMP) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff